## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 2.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($563.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Ulta Beauty Centers Wellness Strategy on Guidance, Education, and Consumer Confidence**
- Source: BuzzFeed | 20251217T060856 | Bullish | Relevance: 100%
- Ulta Beauty is focusing its wellness strategy on guidance, education, and consumer confidence, treating wellness as an extension of beauty. Through consumer data from its 46 million Rewards members, Ulta filters fleeting trends, building credible long-term categories and helping shoppers navigate choices with confidence. The company has restructured internally to better align various departments, ensuring a more agile and responsive approach to evolving wellness trends and fostering a personalized, experiential journey for its customers.

**2. Ulta Beauty (ULTA): Revisiting Valuation After a Strong Share Price Run**
- Source: Simply Wall Street | 20251217T040854 | Neutral | Relevance: 100%
- Ulta Beauty (ULTA) has seen a strong share price run, outperforming broader retail with an 11% climb over the past month and high 30s year-to-date gains. While its narrative fair value suggests it's 2.3% undervalued at $603, market ratios flash caution with the stock trading at 22 times earnings, higher than the US specialty retail average of 20.3 times. Investors are questioning whether Ulta still offers mispriced growth or if its future potential is already priced in, especially considering risks like persistent wage inflation and the potential loss of its Target partnership.

**3. Ulta Beauty adopts new executive severance plan for involuntary terminations**
- Source: Investing.com | 20251218T230927 | Somewhat-Bullish | Relevance: 100%
- Ulta Beauty Inc. has implemented a new executive severance plan for involuntary terminations without cause, offering severance equal to two times base salary, a cash lump sum bonus, and up to 12 months of COBRA premiums. This plan replaces previous severance protections for executive officers, with the exception of those under the 2017 change in control plan. The company's stock is trading near its 52-week high, and multiple analysts have recently revised earnings expectations upward, reflecting a positive outlook.

**4. Ulta Beauty adopts new executive severance plan for involuntary terminations By Investing.com**
- Source: Investing.com UK | 20251218T223240 | Somewhat-Bullish | Relevance: 100%
- Ulta Beauty Inc. (NASDAQ:ULTA) has adopted a new Executive Severance Plan that provides severance benefits to executive officers in cases of involuntary termination without cause. This new plan offers two times their base salary over 24 months, a cash lump sum annual bonus, and up to 12 months of COBRA premium payments, subject to the executive providing a general release of claims and complying with restrictive covenants. This update comes as Ulta Beauty's stock is trading near its 52-week high, with several analysts recently raising their price targets due to strong financial performance.

**5. Zacks Research Forecasts Stronger Earnings for Ulta Beauty**
- Source: MarketBeat | 20251218T135710 | Bullish | Relevance: 100%
- Zacks Research has increased its FY2026 EPS estimate for Ulta Beauty to $25.30, surpassing the consensus forecast of $23.96, and also provided a Q4 2027 EPS estimate of $8.42. This follows Ulta's recent strong quarterly performance, where it exceeded revenue and EPS expectations. Analysts generally maintain a "Moderate Buy" rating for Ulta, with an average target price of $576.50, indicating positive sentiment for the stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.52 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.8B |
| Beta | 0.87 |
| 52W Range | $309.01 - $611.90 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.52 |
| Forward P/E | 21.1 |
| Current P/E | 23.4 |
| YoY Growth | 10.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.6% to 0.4% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.49), confirming momentum. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.39% (CS: 62) | Neutral |
| RSI_14 | 64.4 | Neutral |
| MACD Histogram | 1.49 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.107x | Above |
| vs SMA200 | 1.254x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $597.88
- **Stop Loss:** $563.00 (5.8% risk)
- **Target:** $632.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $14,947.00
- **Portfolio %:** 14.95%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.8% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*